|
|
Pediatric Research
  Pediatric research in Colorado reflects the combined efforts of the pediatric faculty who are primarily located at the adjacent campuses of The new Children's Hospital (TCH) at Fitzsimons and the University of Colorado at Denver and Health Sciences Center (UCDHSC) Anschutz Medical Campus.
In 2006, the Department of Pediatrics had more than $85.5 million in research grants. We are ranked second among all medical school-based Departments of Pediatrics in National Institutes of Health (NIH) research funding. At multiple levels, the affiliation between our institutions has translated into more funding and more "muscle" for the research programs underway at UCDHSC, TCH and the combined Fitzsimons and Anschutz Medical Campus.
The Pediatric Clinical Translational Research Center (Pediatric CTRC) at The Children's Hospital is one of only six exclusively pediatric research programs in the US funded by the NIH. The Pediatric CTRC receives approximately $3.6 million annually in direct NIH funding, which helps to support the more than 100 research protocols that are active at the Center at any one time.
The Children's Hospital Research Institute (TCHRI) was established in 1992 as a means of increasing the role of The Children's Hospital and community philanthropy in research. At present, support is directed toward funding promising pediatric scientists and pioneering new ideas. The intent is to achieve maximum return on what is a small but growing investment in pediatric research. The TCHRI supports new research initiatives in all disciplines found at TCH (for example nursing and pathology). A Clinical Trials Organization was established at The Children's Hospital to provide additional support to physicians on the medical staff who participate in and supervise clinical trials.
One example of the broad impact of research conducted by the Department of Pediatrics at Children's is the pioneering work of pulmonologist Steven Abman, MD, and neonatologist John Kinsella, MD. Their work on the life-saving impact of inhaled nitric oxide for premature babies with pulmonary hypertension has led to a multicenter, $7.0 million study of the clinical effect of nitric oxide. Another example is the increasing number of intellectual property (IP) disclosures that are being processed by the Technology Transfer Office (TTO), including those by Drs. D. Graham, R. Garcea, B. Tseng, M. Duncan and R. Shandas.
|
|
